Exelixis Earnings Call Transcripts
Fiscal Year 2026
-
CABOMETYX drives strong sales and strategic focus in GI/GU oncology, with Zanzalintinib advancing in pivotal studies and a December PDUFA. Expansion into CRC and NET, disciplined BD, and innovative pipeline assets position the company for continued growth.
-
Revenue reached $2.123 billion with guidance for $2.4 billion in 2026, driven by RCC and NET launches. Zanza is positioned for a $5 billion+ opportunity with seven pivotal studies, while STELLAR-303 and -304 aim to set new standards in CRC and non-clear cell RCC.
-
Recent ASCO GU data in RCC showed PFS benefit but no significant OS improvement, influencing a shift toward sequential treatment strategies and highlighting the importance of quality of life and toxicity profiles. Key trials like LITESPARK-033 and STELLAR-304 aim to redefine standards in RCC, while STELLAR-303 in CRC demonstrated a survival advantage, supporting strong growth projections for 2026.
-
The discussion highlighted a strategic shift toward building multiple oncology franchises, with zanzalintinib poised for launch and pivotal trials underway. Strong commercial growth continues, especially in RCC and NET, while new combinations and indications are being pursued to sustain long-term relevance.
-
The session highlighted a franchise-driven strategy in oncology, with strong 2025 financials and robust 2026 guidance. Growth is anchored by cabozantinib and zanzalitinib, supported by a multidimensional pipeline and disciplined capital allocation.
Fiscal Year 2025
-
2025 saw robust revenue and net income growth, led by CABOMETYX's dominance in RCC and neuroendocrine tumors, and preparations for the launch of zanzalintinib in CRC. The company remains focused on expanding its oncology franchises, advancing pivotal trials, and maintaining strong capital allocation.
-
Significant progress in advancing multi-franchise oncology platforms, with zanzalitinib emerging as a new backbone supported by positive pivotal trial data and regulatory filings. Multiple late-stage and early-stage assets target high unmet needs in RCC, CRC, and NETs, with strong commercial growth expected.
-
Strong Q3 revenue growth was driven by kidney cancer and a successful NET launch, with plans to expand the GI salesforce and pipeline. Zanzalintinib showed positive CRC data, with an NDA submission planned and new pivotal studies in CRC and RCC underway.
-
Q3 2025 saw strong revenue and net income growth, led by Cabozantinib's leadership in RCC and rapid expansion in NETs, while Zanzalintinib achieved pivotal trial success in CRC. Guidance was raised, R&D expenses lowered, and a new $750M share repurchase was authorized.
-
The discussion highlighted a disciplined, patient-focused approach to oncology innovation, with a robust pipeline led by cabozantinib and zanzalintinib. Strategic collaborations, rigorous portfolio management, and a nimble culture underpin efforts to build multiple franchises and sustain growth beyond key patent expiries.
-
The conference highlighted strong commercial performance and future growth plans, with CABOMETYX projected to reach $3B by 2030 and Zanza expected to drive $5B in revenue by 2033. Zanza's broad clinical program and strategic pipeline prioritization aim to ensure leadership in multiple cancer indications.
-
The conference highlighted robust growth in oncology, with CABOMETYX driving revenue and new NET approvals expanding market reach. Zanza is positioned as the next major franchise, supported by positive clinical data and a disciplined R&D approach. Financial strength enables continued investment and shareholder returns.
-
The conference highlighted ongoing growth of the CABOMETYX franchise, the successful launch of a new NET indication, and the strategic development of zanzalintinib with positive pivotal trial results. The company is focused on expanding its oncology pipeline and building multi-indication franchises.
-
Strong commercial growth in oncology, especially kidney cancer, is driven by cabozantinib, with new launches in NETs and a robust pipeline led by zanzalintinib. The company targets multi-franchise expansion, maintains disciplined R&D and capital allocation, and plans a smooth transition as key patents expire.
-
Q2 2025 saw 19% year-over-year revenue growth, driven by strong cabozantinib demand and a successful NET launch. The pipeline advanced with positive CRC data, while capital was allocated to high-value opportunities. Guidance was reiterated, and share repurchases continued.
-
Six pivotal Zanza studies are underway, with two readouts expected this year. The $5B market opportunity is balanced across GI, GU, and head and neck cancers, with a focus on capital-efficient partnerships and clinical differentiation through improved combinability and patient adherence.
-
Strong ASCO presence and robust Q1 results underscore momentum, with Cabometyx gaining share and Zanzalintinib advancing in pivotal trials. Strategic focus on disciplined R&D, external innovation, and shareholder returns supports growth and market expansion.
-
Strong Q1 results and robust long-term data support continued growth in RCC and a promising NET launch. Pipeline advances include dual primary endpoints in CRC, a tolerability-focused head and neck study, and a novel bispecific antibody entering early clinical trials.
-
Strong demand for Cabo in RCC is fueling growth, enabling investment in new indications and pipeline assets. Zanza, designed for improved tolerability, is advancing through pivotal trials with key readouts expected this year, supporting ambitious long-term sales targets.
-
Strong Q1 growth was driven by RCC market share gains and disciplined capital deployment, including major share buybacks. Pipeline advances in NET, CRC, and non-clear cell RCC, plus strategic Merck collaboration, position the company for continued expansion and franchise building.
-
Q1 2025 saw robust revenue and net income growth, driven by Cabometyx's strong RCC performance and new NET approvals. Guidance for 2025 was raised by $100 million, with continued momentum expected from both core and new indications.
-
Cabozantinib is projected to reach $2B in 2024 and $3B by 2030, with growth driven by RCC and potential new indications. Zanzalintinib, a next-gen TKI, targets a $5B market with pivotal trial readouts expected soon, focusing on areas without cabozantinib overlap.
-
Resilient supply chain and stable FDA relations support a major upcoming launch, with 80% prescriber coverage and a $1B market opportunity. Multiple pivotal data readouts and strategic collaborations are expected to drive growth, while R&D spending remains disciplined.
-
Guidance for 2024 net product sales is $1.95–$2.05B, with strong growth expected and potential upside from CABINET approval. Multiple pivotal trials for Zanza and other pipeline assets are progressing, with key data readouts anticipated in the second half of the year.
-
Strong commercial momentum and pipeline expansion are driving growth, with cabozantinib maintaining leadership in RCC and pivotal data for zanzalintinib and NETs expected in 2025. The company is launch-ready for NETs and aims for $3 billion revenue by 2030.
-
Strong 2024 financials and commercial growth were driven by cabozantinib, with a robust pipeline led by zanzalintinib targeting multiple pivotal trials and launches. The company is well-capitalized, investing in R&D and share buybacks, and aims for continued leadership in GU and GI oncology.
Fiscal Year 2024
-
Q4 2024 revenues rose to $567M, with U.S. Cabo franchise up 20% year-over-year and global revenues at $2.5B. Launch readiness for NET and pivotal Zanza trials signal strong 2025 momentum, supported by a robust balance sheet and ongoing share repurchases.
-
Momentum continues with strong cabozantinib performance, strategic planning for neuroendocrine tumor launches, and a transition to zanzalintinib as a next-gen TKI. Key milestones include a $3B revenue target for cabo by 2030, $5B for zanza by 2033, and pivotal data readouts in 2025.
-
Clarity on cabozantinib's LOE and strong Q3 results set the stage for growth, with $3B U.S. Cabo revenue targeted by 2030 and $5B Zanza by 2033. Pipeline strategy emphasizes differentiated assets, rapid go/no-go decisions, and major opportunities in kidney, NET, GI, and prostate cancers.
-
Recent collaborations and positive trial outcomes have set the stage for growth, with Zanzolitanib positioned as a next-generation TKI targeting improved safety and efficacy. Multiple pivotal studies and a robust early-stage pipeline support long-term expansion, while financial discipline and strategic partnerships enhance flexibility.
-
Recent events include a Merck collaboration and patent clarity, supporting a strong outlook. Focused on high-conviction deals in GI/GU oncology, the company sees continued growth for Cabo and projects Zanza to reach $5B in U.S. sales by 2033, with pivotal data expected in 2025.
-
Cabometyx continues to drive revenue growth in RCC, with label expansion in NETs seen as a major opportunity. Zanzalintinib is advancing through multiple pivotal trials, supported by a Merck collaboration, and the pipeline is expanding in GU/GI oncology with a focus on science-driven, commercially viable assets.
-
Q3 2024 saw robust revenue and net income growth, driven by the Cabo franchise and a favorable ANDA ruling extending exclusivity. Zanza's collaboration with Merck and a strong pipeline position the company for multi-year growth, with raised 2024 guidance and significant market opportunities ahead.
-
Ongoing patent litigation and settlements define future generic entry, while new indications in NET and prostate cancer are set to drive growth from 2025. Strategic capital allocation, pipeline prioritization, and recent ESMO data support a multi-product oncology focus.
-
The company is advancing its oncology portfolio with CABOMETYX maintaining leadership in RCC and expanding into NETs and CRPC, supported by robust clinical data. Zanzarlitinib is progressing through pivotal studies in CRC and RCC, while early-stage R&D focuses on ADCs and synthetic lethality.
-
Significant progress was highlighted in cabozantinib's expansion, with strong Q2 revenue and pivotal CABINET data supporting new indications. Zanzalitinib's pivotal trials are advancing, with 2025 set for key readouts. The pipeline is prioritized for innovation and commercial impact.
-
Q2 2024 saw record revenues and net income, driven by strong CABOMETYX performance in RCC and milestone payments. Regulatory progress included FDA acceptance of cabozantinib for NET, while pipeline and capital allocation strategies remain disciplined and focused on growth.
-
CABOMETYX remains the main revenue driver, with new indications in prostate cancer and neuroendocrine tumors poised to boost growth pending regulatory filings. Zanzalitinib advances in three pivotal studies, while $1 billion in buybacks and minimal macro risks reflect strong financial and operational positioning.